Folgen
-
In the latest episode Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. Tom gives an insight into the world of protein engineering, how it’s an invaluable tool for improving the stability, functionality, and applicability for drug products. He comments on some aspects of the field that are particularly exciting at the minute, discussing some of the key aspects of antibody drugs, the potential for bispecifics in improving functionality, but also considering the parts such as genomics for creating a wider knowledge base, and in the future using computational design and AI to develop drugs more safely.
-
Lucy Chard, Digital Editor for CPHI Online discusses womens’ health, and more specifically about women’s representation in clinical trials and the associated ripple effects with Emma Banks, CEO of Ramarketing. The podcast highlights the social and medical implications and bias’ that lead to disparity and the complexities around this.
Also covered is the need for solutions in combatting bias, such as by using tools including education and technology, and cross-sector collaboration. Banks highlighted how important it is to acknowledge the differences and work with them to change the lived mindset and make safer, more effective medicines.
-
Fehlende Folgen?
-
In this episode we’re focusing on some of the work from one of our valued partners at CPHI, the PSCI. The PSCI have recently published the results from their audits and to talk us through these Digital Editor Lucy Chard is joined by Birgit Skuballa. Skuballa represents Bayer in the PSCI as Chair of the PSCI Audit Committee, and gives us a information on how these audits work, the different pillars across the pharmaceutical industry that the audits address, how this changes regionally, and importantly, how the PSCI work with their members afterwards to improve their practices.
-
On this episode of the podcast I’m joined my marketing specialist and entrepreneur, Raman Sehgal. Sehgal is the founder of several companies, including life science marketing company Ramarketing. In this podcast Raman and I discuss the different ways marketing can help companies in achieving their goals, whether it’s in how to go about finding the right partner, creating the right messaging around a companies’ ESG values, or how to attract talent. We also go on to talk about the future of digital marketing, especially the increased use of AI in today’s world, how much this has changed everyday practices already, and the scope of what is to come.
-
Daniel Mora-Brito joins Lucy Chard to discuss the health landscape in the African continent, covering some of the greatest threats seen there over the years and that are still impacting people’s lives on a daily basis, helping to drive home the importance of improved, localised healthcare in the continent. Lucy and Daniel talk about the economic factors that underpin a lot of the transformations across the region, from the perspective of those on home turf and the companies from different regions looking to invest and expand into this space. Daniel mentions the different actors in the region and what expanding capacities in Africa will mean for patient access in a rapidly expanding population.
-
This podcast episode aims to explain the importance and intricacies of developing excipients and then goes into more depth regarding the excipient market, how this differs globally, what tactics different companies are now using to gain ground and push the field forward to be able to develop more innovative drug delivery systems.
Digital Editor Lucy Chard is joined by Nick DiFranco, MEM, the Global Market Manager for Novel Pharmaceutical Excipients at Lubrizol Life Science.
Lubrizol is a pioneer in the novel excipient development space so DiFranco can give a deep level of insight into the field as it stands, some of the innovative products they’re developing at Lubrizol, and the trends to look out for the in future.
-
Welcome to the last episode of 2023! Digital Editor Lucy Chard is joined by her team in a special retrospective episode to close out the year. Guests Vivian Xie, Editor for CPHI Online and Tara Dougal, Content Director for Pharma, discuss their highlights from the year; diversity, sustainability, and the CPHI Barcelona event cropping up as top features. The Women in Pharma series that Vivian has worked on for the past year has been a resounding success, some of our most impactful content on CPHI Online, which, as arguably some of our most important content we are so pleased to see that reflected with our audience. We also cover sustainability, drug approvals, Alzheimer's research, mRNA oncology vaccines, and digital marketing for pharma companies.
To see more about everything we mentioned in the podcast, see the links below:
Women in Pharma Interviews
Women in Pharma: Advancing gender diversity & healthcare equality - https://www.cphi-online.com/women-in-pharma-advancing-gender-diversity-news121441.html
Women in Pharma: Empowering yourself and other women in pharma - https://www.cphi-online.com/women-in-pharma-empowering-yourself-and-other-news122294.html
Sustainability
CPHI Sustainability Trend Report 2023: Towards a Greener Future - https://www.cphi-online.com/cphi-sustainability-trend-report-2023-towards-a-news121332.html
CPHI Podcast Series: An insight into the Chief Sustainability Officer - https://www.cphi-online.com/cphi-podcast-series-an-insight-into-the-chief-news120741.html
CPHI Podcast Series: Sustainable Strategies in the Pharmaceutical Packaging Industry - https://www.cphi-online.com/cphi-podcast-series-sustainable-strategies-in-the-news119779.html
Top Content
Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook - https://www.cphi-online.com/your-prescription-for-marketing-success-digital-news121086.html
10 Major Drug Approvals So Far in 2023 - https://www.cphi-online.com/10-major-drug-approvals-so-far-in-2023-news121294.html
CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond - https://www.cphi-online.com/cphi-podcast-series-exploring-neurological-news122273.html
The CPO Starter Pack: Why and When to Bring in a Contract Packaging Partner - https://www.cphi-online.com/the-cpo-starter-pack-why-and-when-to-bring-in-a-news120889.html
Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity -
-
In this special post-CPHI Barcelona episode, host Lucy Chard speaks to Matthew Wise from CCD Partners about the Start-up Market held at the event. In this podcast they speak about the event, which for the first time held a specific area for Start-up companies, something that is particularly applicable to the Catalan region as a leading area for innovation in pharma and healthcare, they also talk about discuss what this start-up market means for the companies, as well as for investors and potential partners, and for the future of pharma innovation.
-
This episode covers the recent changes in legislature around drug pricing in the USA, and what this means for the global pharma market, as well as the impact it will have on the US population in terms of access to medicine. The price negotiations with Medicare are targeting medications used in the treatment of many chronic diseases such as cardiovascular disease and diabetes. We will take a look at what this means for people with chronic disease, and conversely the impact on the individual pharma companies and then more widely, on innovation in the industry.
-
Digital Editor for CPHI Online, Lucy Chard, is joined by Alan Palmer of Elixa MediScience to talk about neurological disorders including Alzheimer’s disease and everything that is encompassed under this terminology, spanning the history of disease, the social impacts, the different modalities and developments in therapeutics, and what the future of research into care in this field holds.
-
Digital Editor Lucy Chard speaks with Bill Whitford of DPS Groupabout the integration of AI in healthcare. Bill gives context to the use of AI in different aspects of medicine and drug discovery, including how it can help revamp drug repurposing strategies and save time when searching for drug targets. We also see the implications the technology could have socially, by helping to eliminate bias in clinical trials, and the prospect of how far AI could go.
-
In this episode of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenahrey, the President and CEO of PharmaAdvice. Sandra has 35 years of experience in the Life Sciences industry, working with giants in the pharma field throughout Latin America, Canada, and parts of Asia. In this interview, Sandra discusses the practicalities of nearshoring, the benefits it gives to companies as well as individuals, and the effects it has socially and economically on a global scale.
-
Gil Roth, President of the Pharma & Biopharma Outsourcing Association, delves into the most exciting aspects of outsourcing and manufacturing in this interview, including some of the biggest areas of innovation and technology, such as cell and gene therapeutics. We also get an update on the industry as a whole since the COVID-19 pandemic and how companies are adapting to changes in the market and regional trends.
-
In this episode from the CPHI Podcast Series Louise Duffy and Campbell Bunce from Abzena speak to Digital Editor Lucy Chard, using their cumulative knowledge to give an overview of the drug development and manufacturing processes, demonstrating all of the aspects that go into such an undertaking as making a new drug for a patient population.
They highlight some of the key areas that teams have to work on, the detailed analysis that has to take place at each stage, as well as within the wider context with regulations to consider, and finally they highlight some of the key areas for innovation and for expanding knowledge in the field.
-
In this episode Digital Editor Lucy Chard finds out more about being the Chief Sustainability Officer in the pharmaceutical industry from Nic Hunt, Global Head of Sustainability at Nelipak Healthcare Packaging.
In the podcast we discuss what it means to be in the role of a Chief Sustainability Officer, how the role is set to develop along with more established sustainability teams. The role they provide is so integral to the overall health of a pharma company, the pharma supply chain and subsequently the health of the planet. Hunt's optimism about the industry making real changes to how they work and meeting goals such as Net Zero really comes across, with the outlook for the future of sustainability in pharma a bright one.
-
The podcast focused on the 30 year anniversary of Ursatec in the provision of preservative-free pharmaceuticals, medical devices and cosmetics. We took a look through the Ursatec portfolio, the importance of safety and sustainability in their products, and what the future holds for the company.
-
As part of celebrating International Women’s Day on the 8th March 2023, we wanted to highlight the importance of supporting women’s health. Historically, women’s medicine, in relation to diseases, and sexual and reproductive rights, has been chronically overlooked in the wider field. We hope to use this podcast with special guest Dr Charlotte Fairweather, to open up a wider conversation about educating and empowering women so they can access the healthcare they need.
-
Rare disease is an often overlooked field of medicine, but one which is rapidly gaining ground, which is certainly a good thing as rare diseases affect around 300 million people globally.
By their nature, rare diseases are incredibly difficult to research and develop medicines for, but this just makes it all the more urgent to fulfil this unmet need for rare disease patients.
In this podcast I am joined by Rachel Smith; Rachel is the Executive Director, Global Head of Rare Diseases at Parexel. Rachel brings more than a decade of experience in every development phase of rare disease and cell and gene therapy clinical trials to her work with Parexel’s rare disease clients.
Previously, she served as Vice President of Clinical Operations, Portfolio Director of Rare Disease, and Global Head of the Cell & Gene Center of Excellence at Veristat LLC. She led programs in ADA-SCID, Canavan disease, congenital adrenal hyperplasia, Fabry disease, Gaucher disease, metachromatic leukodystrophy, and Wiskott-Aldrich Syndrome. Rachel has expertise in clinical development strategy, novel and adaptive trial design, decentralized trials, and other creative solutions for rare disease products with a non-classical route to market.
-
Sustainability in pharma is now gaining the recognition it deserves, quickly becoming one of the biggest priorities for pharma companies across the spectrum.
Upgrading this Packaging in pharma comes in all shapes and sizes – whether we are talking about replacing single use plastics in manufacturing, or waste management at the end of the commercial chain.
Today we will be talking about sustainability in the pharmaceutical packaging industry, how it can be more ingrained and the impact it will have, with an expert from a leading European packaging company, Adelphe. Félicie Pachot is the Health Marketing Manager at Adelphe and she goes into the model Adelphe uses to support sustainable practices through recycling, reduction of waste, and resue.
-
In this latest episode from the CPHI Podcast Series, Digital Editor Lucy Chard speaks to Sanjay Sharma, Global Head of Manufacturing, from Dr Reddy’s. Sanjay has over 26 years of experience in roles encompassing sales, the supply chain, and technical operations.
Pharma 4.0 is the upgrading of the pharma industry to a more digitalised state, including automation of processes and greater system integration. This has a wealth of advantages, such as leading to greater compliance and quality control in the manufacturing process. Pharma 4.0 also leads to increasing the sustainability of many aspects of the pharmaceutical chain. Dr Reddy’s is a leading pharmaceutical company and is at the forefront of adopting industry 4.0 into their everyday systems.
Dr Reddy’s largest manufacturing facility in Bachupally, Hyderabad, India, recently joined the Global Lighthouse Network of the World Economic Forum, a network of over 100 manufacturing companies committed to developing and leading the progression into Industry 4.0 technologies.
This commitment from Dr Reddy’s will help to reduce manufacturing costs, production lead time, and energy consumption, as well as increasing the quality assurance throughout the manufacturing process.
- Mehr anzeigen
